Immunoreactivity evaluation of a new recombinant chimeric protein against Brucella in the murine model
,
Abstract
Background and Objectives: Brucellosis is an important health problem in developing countries and no vaccine is available for the prevention of infection in humans. Because of clinically infectious diseases and their economic consequences in human and animals, designing a proper vaccine against Brucella is desirable. In this study, we evaluated the immune responses induced by a designed recombinant chimera protein in murine model.
Materials and Methods: Three immunodominant antigens of Brucella have been characterized as potential immunogenic and protective antigens including: trigger factor (TF), Omp31 and Bp26 were fused together by EAAAK linkers to produce a chimera (structure were designed in silico), which was synthesized, cloned, and expressed in E. coli BL21 (DE3). The purification of recombinant protein was performed using Ni-NTA agarose. SDS-PAGE and anti-His antibody was used for confirmation purified protein (Western blot). BALB/c immunization was performed by purified protein and adjuvant, and sera antibody levels were measured by ELISA. otted.
Results: SDS-PAGE and Western blotting results indicated the similarity of in silico designing and in vitro experiments. ELISA result proved that the immunized sera of mice contain high levels of antibodies (IgG) against recombinant chimeric protein.
Conclusion: The recombinant chimeric protein could be a potential antigen candidate for the development of a subunit vaccine against Brucella.
Seleem MN, Boyle SM, Sriranganthan N. Brucellosis:
A reemerging zoonosis. Vet Microbiol 2010; 140:392-398.
Pappas G. The changing Brucella ecology: novel reser- voirs, new threats. Int J Antimicrob Agents 2010; 36:8-11.
Fugier E, Pappas G, Gorvel JP. 2007. Virulence factors in brucellosis: implications for aetiopathogenesis and treatment. Exp Rev Mol Med 2007; 9:1-10.
He Y. 2012. Analyses of Brucella pathogenesis, host
immunity, and vaccine targets using systems biology
and bioinformatics. Front Cell Infect Microbiol 2012;2:1-17.
Nicoletti P. Brucellosis: past, present and future. Prilozi
; 31:21–32.
Perkins SD, Smither SJ, Atkins HS. Towards a Brucella
vaccine for humans. FEMS Microbiol Rev 2010;34:379-394.
Costa Oliveira S, Costa Macedo G, Augusto de Almeida
L, Souza de Oliveira F, Oñate A, Cassataro J, et al.
Recent advances in understanding immunity against
brucellosis: application for vaccine development. Open
Vet Sci J 2010; 4:102-108.
Dorneles EM, Sriranganathan N, Lage AP. Recent
advances in Brucella abortus vaccines. Vet Res 2015;
:76.
He Y, Xiang Z. Bioinformatics analysis of Brucella
vaccines and vaccine targets using VIOLIN. Immunome
Res 2010; 6 (Suppl. 1), S5.
Avila-Calderón ED, Lopez-Merino A, Sriranganathan
N, Boyle SM, Contreras-Rodríguez A. A history of
the development of Brucella vaccines. Biomed Res Int
;2013-743509.
Cassataro J, Estein SM, Pasquevich KA, Velikovsky
CA, Barrera S, Bowden R, et al. Vaccination with
the recombinant Brucella outer membrane protein
or a derived 27-amino-acid synthetic peptide elicits
a CD4+ T helper 1 response that protects against
Brucella melitensis infection. Infect Immun 2005;73:8079-8088.
Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati
CA, Baldi PC, et al. Antibody reactivity to Omp31
from Brucella melitensis in human and animal infections
by smooth and rough Brucella. Clin Diagn Lab Immunol 2004; 11:111-114.
Cassataro J, Pasquevich KA, Estein SM, Laplagne DA,
Zwerdling A, Barrera s, et al. A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of
protection against B. ovis and a similar degree of protection
against B. melitensis than Rev.1 vaccination.Vaccine 2007; 25:5958–5967.
Qiu J, Wang W, Wu J, Zhang H, Wang Y, Qiao J, et al.
Characterization of periplasmic protein BP26 epitopes
of Brucella melitensis reacting with murine monoclonal
and sheep antibodies. PloS One 2012; 7: e34246.
Seco-Mediavilla P, Verger JM, Grayon M, Cloeckaert
A, Marin CM, Zygmunt MS, et al. Epitope mapping
of the Brucella melitensis BP26 immunogenic protein:
usefulness for diagnosis of sheep brucellosis. Clin Diagn
Lab Immunol 2003; 10:647-651.
Cloeckaert A, Baucheron S, Vizcaino N, Zygmunt MS.
Use of recombinant BP26 protein in serological diagnosis
of Brucella melitensis infection in sheep. Clin Diagn Lab Immunol 2001; 8:772-775.
Debbarh HS, Zygmunt MS, Dubray G, Cloeckaert A.
Competitive enzyme-linked immunosorbent assay us- ing monoclonal antibodies to the Brucella melitensis BP26 protein to evaluate antibody responses in infect- ed and B. melitensis Rev.1 vaccinated sheep. Vet Micro- biol 1996; 53:325-337.
Yang X, Walters N, Robison A, Trunkle T, Pascual DW.
Nasal immunization with recombinant Brucella meli- tensis bp26 and trigger factor with cholera toxin reduc- es B. melitensis colonization. Vaccine 2007; 25:2261-2268.
Deuerling E, Patzelt H, Vorderwulbecke S, Rauch T, Kramer G, Schaffitzel E, et al. Trigger factor and DnaK possess overlapping substrate pools and binding speci- ficities. Mol Microbiol 2003; 47:1317-1328.
Ghasemi A, Ranjbar R, Amani J. In silico analysis of chimeric TF, Omp31 and BP26 fragment of Brucella melitensis for development of a multi subunit vaccine candidate. Iran J Basic Med Sci 2014; 17:172-180.
Yang X, Skyberg JA, Cao L, Clapp B, Thornburg T, Pascual DW. Progress in Brucella vaccine develop- ment. Front Bio 2013; 8:60-77.
He Y. Analyses of Brucella pathogenesis, hostimmuni- ty, and vaccine targets using systems biology and bio- informatics. Front Cell Infect Microbiol 2012; 2:2.
Olsen S. Recent developments in livestock and wildlife brucellosis vaccination. Revue Scientifique et Tech- nique (International Office of Epizootics) 2013; 32:207-217.
Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis
vaccines: past, present and future. Vet Microbiol 2002;
:479-496.
Skendros P, Boura P. Immunity to brucellosis. Rev Sci
Tech 2013; 32:137-147.
| Files | ||
| Issue | Vol 8 No 3 (2016) | |
| Section | Articles | |
| Keywords | ||
| Brucella vaccine immunity recombinant | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
